Collagen Matrix received FDA 510(k) approval for Fibrillar Collagen Wound Dressing
On June 29, 2022, Collagen Matrix, Inc., a leader in regenerative medicine, a global manufacturer of collagen and other biomaterial-based medical devices, and Linden Capital Partners portfolio company announced FDA 510(k) Clearance for a Fibrillar Collagen Wound Dressing, product offerings into the advanced wound care market.
The Collagen Matrix Fibrillar Collagen Wound Dressing is an absorbent microfibrillar matrix designed to handle moderately to severely exuding wounds and prevent mild bleeding. When a dressing is put immediately on a wound bed, it begins to absorb exudates a...
